Table 1 Demographic information, comorbidities, immunosuppression, and immunodeficiency of patients with COVID-19 and seasonal influenza.
From: Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza
COVID-19 (n = 166) | Influenza (n = 255) | P value | |
|---|---|---|---|
Female, no. (%) | 55 (33.1) | 111 (43.5) | 0.03 |
Age, median (IQR) | 59 (45; 71) | 66 (52; 77) | < 0.001 |
Comorbidities | |||
ACCI, mean (SD) | 3.0 (2.6) | 4.0 (2.7) | < 0.001 |
Hypertension, no. (%) | 66 (39.8) | 131 (51.4) | 0.02 |
Cardiovascular disease, no. (%) | 27 (16.3) | 73 (28.6) | 0.003 |
Cerebrovascular disease, no. (%) | 12 (7.2) | 32 (12.5) | 0.10 |
Chronic respiratory disease, no. (%) | 25 (15.1) | 69 (27.1) | 0.004 |
Chronic liver disease, no. (%) | 4 (2.4) | 18 (7.1) | 0.04 |
Chronic renal disease, no. (%) | 13 (7.8) | 48 (18.2) | 0.002 |
Diabetes mellitus, no. (%) | 32 (19.3) | 52 (20.4) | 0.80 |
SOT recipients, no. (%) | 4 (2.4) | 23 (9.0) | 0.007 |
Immunocompromised host | |||
Total, no. (%) | 39 (23.5) | 69 (27.1) | 0.43 |
Corticosteroids, no. (%) | 13 (7.8) | 40 (58.0) | 0.02 |
CNI/mTORI, no. (%) | 6 (3.6) | 29 (42.0) | 0.006 |
MTX, no. (%) | 2 (1.2) | 1 (1.4) | 0.57 |
CD20 antibodies, no. (%) | 9 (5.4) | 2 (2.9) | 0.008 |
Chemotherapy, no. (%) | 20 (12.0) | 11 (15.9) | 0.004 |
Acute leukemia, no (%) | 13 (7.8) | 6 (8.7) | 0.01 |
Lymphoma, no. (%) | 8 (4.8) | 10 (14.5) | 0.81 |
Allogeneic HCT, no. (%) | 5 (3.0) | 7 (10.1) | 1.00 |
